Results 11 to 20 of about 49,641 (173)

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions [PDF]

Journal of Pharmacy & Pharmaceutical Sciences, 2021
Purpose: Remdesivir, a drug originally developed against Ebola virus, is currently recommended for patients hospitalized with coronavirus disease of 2019 (COVID-19).
Subrata Deb, Anthony Allen Reeves
doaj   +3 more sources

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study [PDF]

Infectious Diseases and Therapy, 2023
Introduction In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, Kavita Juneja, Monica Ramchandani, Joshua T. Schiffer, Carlos Vaca, Robert L. Gottlieb, Yuan Tian, Emon Elboudwarej, Joshua A. Hill, Richard Gilson, Lauren Rodriguez, Charlotte Hedskog, Shuguang Chen, Jairo M. Montezuma-Rusca, Anu Osinusi, Roger Paredes   +17 more
doaj   +2 more sources

Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis [PDF]

Swiss Medical Weekly, 2023
AIMS OF THE STUDY: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by
Janne Estill, Plamenna Venkova-Marchevska, Huldrych F. Günthard, Sara Botero-Mesa, Amaury Thiabaud, Maroussia Roelens, Laure Vancauwenberghe, Lauro Damonti, Ulrich Heininger, Anne Iten, Peter W. Schreiber, Rami Sommerstein, Sarah Tschudin-Sutter, Nicolas Troillet, Danielle Vuichard-Gysin, Andreas Widmer, Torsten Hothorn, Olivia Keiser   +17 more
doaj   +5 more sources

Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis [PDF]

Journal of Investigative Medicine High Impact Case Reports, 2023
End-stage kidney disease (ESKD) has been shown to be correlated with an increased risk of COVID-19 infection and mortality. Remdesivir is an effective non-EUA U.S.
Ryan Geffin MD, Shazia Raheem PharmD, Lavannya M. Pandit MD, MS, Andrew S. Hunter PharmD, Michael W. Holliday MD, PhD, Aditya V. Rao, Maulin K. Shah MD   +6 more
doaj   +3 more sources

The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis

Therapeutic Advances in Drug Safety, 2021
Introduction: Remdesivir, an experimental antiviral drug has shown to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), both in vitro and in vivo .
Chenchula Santenna, Kota Vidyasagar, Krishna Chaitanya Amarneni, Sai Nikhila Ghanta, Balakrishnan Sadasivam, Saman Pathan, R. Padmavathi   +6 more
doaj   +1 more source

Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study

Antibiotics, 2022
The benefits of remdesivir treatment, with or without co-administration of antibiotics such as azithromycin, are uncertain in COVID-19 pneumonia. The aim of this retrospective single-center study was to assess the effects of remdesivir, with or without ...
Andrea Ticinesi, Domenico Tuttolomondo, Antonio Nouvenne, Alberto Parise, Nicoletta Cerundolo, Beatrice Prati, Ilaria Zanichelli, Angela Guerra, Nicola Gaibazzi, Tiziana Meschi   +9 more
doaj   +1 more source

Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations

Frontiers in Pharmacology, 2021
Development of new drugs is a time-taking and expensive process. Comprehensive efforts are being made globally toward the search of therapeutics against SARS-CoV-2.
Faez Iqbal Khan, Tongzhou Kang, Haider Ali, Dakun Lai   +3 more
doaj   +1 more source

Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials

Frontiers in Pharmacology, 2022
Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million.
Zhenchao Wu, Zhenchao Wu, Zhifei Han, Zhifei Han, Beibei Liu, Beibei Liu, Ning Shen, Ning Shen   +7 more
doaj   +1 more source

The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Remdesivir is a monophosphoramidate prodrug of an adenosine analog, and it has a broad-spectrum antiviral activity against paramyxoviruses, flaviviruses, and coronaviruses.
Muhammad Irfan Malik, Sardar Al Fareed Zafar, Muna Malik, Fabiha Qayyum, Iqra Akram, Ammarah Arshad, Khalid Waheed, Jodat Saleem, Abdul Jabbar, Muhammad Junaid Tahir, Zohaib Yousaf   +10 more
doaj   +1 more source

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality [PDF]

, 2021
BACKGROUND: Remdesivir is FDA approved for the treatment of hospitalized patients with COVID-19 and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials.
Balani, B., Bernardino, J. I., Boffito, M., Brainard, D. M., Bruno, R., Castagna, A., Chokkalingam, A. P., De Rosa, F. G., De Wit, S., Diaz, G., Diaz-Cuervo, H., Gottlieb, R. L., Goyal, P., Haubrich, R. H., Hu, H., Kim, S. -W., Kurbegov, D., Lee, I. -H., Lin, L., Lye, D. C., Martinez, E., Mullane, K. M., Olender, S. A., Osinusi, A. O., Perez, K. K., Ripamonti, D., Walunas, T. L., Wang, S., Wu, G.   +28 more
core   +1 more source